Description
Advance your retinal disease research with confidence using a high-quality, isogenic ABCA4 knockout human induced pluripotent stem cell (hiPSC) line, SCTi003-A-3. Derived from the well-characterized SCTi003-A healthy control hiPSC line, SCTi003-A-3 was generated through CRISPR-Cas9-mediated editing of the endogenous ATP-binding cassette sub-family A member 4 (ABCA4) gene, resulting in a complete loss of ABCA4 protein expression. Compatible with STEMdiff™ differentiation protocols, this genome-edited line is an ideal hiPSC model for investigating ABCA4-related retinal disorders, including Stargardt disease, cone-rod dystrophy, and retinitis pigmentosa and is well-suited for drug discovery and therapeutic development of these diseases.
Manufactured under rigorous quality control procedures with a culture system that includes mTeSR™ Plus, Corning® Matrigel® hESC-Qualified Matrix, and ReLeSR™, SCTi003-A-3 performs optimally and reproducibly from batch-to-batch. This line maintains karyotypic stability and trilineage differentiation potential and is registered with hPSCreg® to support ethical sourcing and compliance with international standards.
For control-matched experiments, refer to Healthy Control Human iPSC Line, Female, SCTi003-A. For alternative genotypes, see all of our healthy control human iPSC lines.
This research-use-only product has been consented for both academic and commercial research applications under Institutional Review Board-approved protocols. Whole exome and whole genome sequence data files are available upon request. Please contact us for pricing.
Certain products are only available in select territories. Please contact your sales representative or Product & Scientific Support for further information.
